Ketoisocaproic Acid KIC.
Ketoisocaproic Acid KIC supplementation for targeted health support. KIC is an intermediate metabolite of leucine. Some of it converts to HMB, some to ketone bodies. Theoretical benefit is more direct anti-catabolic signaling than leucine.
Reviewed March 2026
- Category
- Ketone
What Ketoisocaproic Acid KIC is, and what it does.
- Does it work
- The theory is interesting but evidence is weaker than for leucine or HMB directly. For most people, leucine or HMB makes more sense. This is for experimenters.
- How much to take
- 1-3g daily. Less studied than leucine. Doses are extrapolated from metabolite relationships.
- Time to feel it
- There's no acute effect to time. The small trial base followed nitrogen balance and body composition across weeks of daily use.
- The first dose
- Day one is quiet. It's absorbed and either transaminated back to leucine or oxidised within hours, so it registers in amino acid handling rather than in anything you notice.
- With regular use
- Theoretical muscle preservation during caloric deficit. Evidence is weak. May be a minor player in overall muscle protein balance.
- How well tolerated
- Appears well tolerated. Your body makes it naturally from leucine. Limited formal safety studies.
- How it feels
- Nothing dramatic to notice. Any effect registers in body composition and in blood markers of amino acid handling rather than in how a session feels.
- The overlooked benefit
- It's the step your body takes to make HMB. A minor cytosolic enzyme converts it, which is why eating leucine raises circulating HMB at all.
1 to 3g a day is where Ketoisocaproic Acid KIC works.
Source: Van Koevering & Nissen, J Anim Sci 1992; limited human data
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Ketoisocaproic Acid KIC has emerging evidence. Based on 278+ studies.
- Leucine metaboliteBiochemistry establishes this
- Anti-catabolicLimited evidence, theoretical basis
- Better than leucineNo convincing comparative data
- Well tolerated in useNatural metabolite, limited safety studies
Questions people ask about Ketoisocaproic Acid KIC.
- What's the difference between KIC and HMB?
- KIC is one step before HMB in leucine metabolism. Only about 5% of KIC becomes HMB. They're related but different compounds.
- Why not just take leucine?
- Good question. Leucine converts to KIC in your body. The argument for KIC is bypassing that step, but the advantage is unproven.
- Is KIC ketogenic?
- Yes. Part of KIC metabolism produces ketone bodies. But it's not a significant ketone source at normal doses.
- Do any studies support KIC?
- Few. Some older research suggested anti-catabolic effects. More research focuses on leucine and HMB which have better evidence.
- Who would use this?
- Biohackers experimenting with leucine metabolism. Those who don't respond to leucine or HMB. Very niche application.
- Can I stack it with leucine?
- Theoretically yes, but you'd be providing two parts of the same pathway. Likely redundant.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
KIC is the keto acid of leucine, and branched-chain aminotransferase moves an amino group between the two in either direction. Supplying KIC lets the body regenerate leucine while consuming an amino group, and supplying leucine generates KIC.
KIC is converted to HMB by KIC dioxygenase in the cytosol, which is the route by which the body makes HMB. Only a small fraction of leucine flux passes through KIC to reach HMB.
HICA is the reduced hydroxy form of KIC, formed by a dehydrogenase acting on the keto group. The two interconvert with cellular redox state, so they sit on one short branch of leucine metabolism.
Isoleucine's keto acid competes with KIC for the same branched-chain ketoacid dehydrogenase complex and for the same aminotransferase. Loading one branched-chain substrate heavily slows clearance of the others.
Valine's keto acid is handled by the same dehydrogenase complex that oxidises KIC, so the two compete for a single capacity-limited step. Large single-substrate loads shift the balance of branched-chain catabolism.
Branched-chain aminotransferase is a pyridoxal-phosphate enzyme, so the interconversion of KIC and leucine depends on active B6 availability. Without it the amino group cannot be moved onto or off the keto acid.
The E1 component of branched-chain ketoacid dehydrogenase uses thiamine pyrophosphate to decarboxylate KIC. Thiamine status therefore sets the ceiling on branched-chain keto acid oxidation.
The dihydrolipoyl dehydrogenase subunit shared by the branched-chain complex is an FAD enzyme, and FAD is built from riboflavin. The downstream isovaleryl-CoA dehydrogenase is also flavin-dependent.
Oxidation of KIC produces isovaleryl-CoA, so every turn of the pathway consumes a coenzyme A molecule built from pantothenate. Low CoA availability limits how fast the acyl product moves forward.
Further along the leucine route, 3-methylcrotonyl-CoA carboxylase attaches bicarbonate and requires a biotin prosthetic group. That step is specific to this pathway, so biotin status shows up in leucine and KIC catabolism.
The transamination that converts KIC to leucine takes its amino group from glutamate and releases alpha-ketoglutarate. Supplying KIC therefore consumes glutamate nitrogen, which is why KIC is used as a nitrogen acceptor.
A branched-chain amino acid blend feeds directly into the keto acid pool KIC belongs to, using the same aminotransferase and dehydrogenase. Combining them raises total flux through one shared route rather than opening a second one.
The branched-chain ketoacid dehydrogenase complex that oxidises KIC uses lipoamide as its acyl-carrying arm, exactly as pyruvate dehydrogenase does. Lipoic acid is the precursor of that lipoamide group. This is a settled cofactor relationship for the enzyme that consumes KIC, so it is a mechanistic pairing rather than a performance claim.
The first, decarboxylating subunit of the branched-chain ketoacid dehydrogenase complex is thiamine pyrophosphate dependent, and TPP-dependent decarboxylations require a divalent magnesium ion at the active site. Magnesium therefore sits alongside the B vitamins already listed for this pathway.
Leucine becomes KIC by handing its amino group to alpha-ketoglutarate, which makes glutamate, and glutamate is the nitrogen donor that becomes glutamine in muscle. Reading it backwards, KIC can pick an amino group back up and become leucine again. Glutamine and KIC therefore sit on two ends of the same muscle nitrogen shuttle.
Oxidising KIC produces isovaleryl-CoA, and carnitine is the buffer that carries surplus short-chain acyl groups out as acylcarnitines when the CoA pool gets tight. This is why isovalerylcarnitine is a recognised marker of leucine catabolic flux. Carnitine supports the disposal side of the same pathway KIC feeds.
Whey is unusually leucine dense, and KIC is the direct transamination product of leucine. Dosing both means supplying the precursor and its keto-acid at once. The two are not independent inputs, so the combined leucine-equivalent load is the number that matters, not two separate ones.
KIC's own carbon skeleton is ketogenic and does not pass through the B12 step, but the branched-chain ketoacid dehydrogenase complex it shares is the same one that handles the isoleucine and valine ketoacids, and those routes run through propionyl-CoA and methylmalonyl-CoA mutase, which needs adenosylcobalamin. In any product carrying the full branched-chain set, B12 belongs on the cofactor list.
Transaminating KIC back to leucine consumes an amino group, which is why keto-acids have long been studied as a way to take up circulating nitrogen. Ornithine feeds the urea cycle, the other route for disposing of it. The two act on the same problem by different means; the human evidence for the pairing at supplement doses is thin.
Arginine is a urea cycle intermediate and supports the cycle's throughput. If a keto-acid is being used to take up amino nitrogen, the cycle that ultimately clears it is the downstream partner. Mechanistically coherent, not measured as a combination.
Nothing specific on file for Ketoisocaproic Acid KIC. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Ketoisocaproic Acid KIC actually does.
Ketoisocaproic acid, also written 4-methyl-2-oxopentanoate, is the keto-acid of leucine. Branched-chain aminotransferase strips leucine's amino group onto alpha-ketoglutarate and what is left is KIC.
That transamination runs both ways. Given an available amino donor, KIC is converted back to leucine, which is why it is described as a nitrogen-free way to supply leucine carbon.
The committed, irreversible step is branched-chain ketoacid dehydrogenase, which decarboxylates KIC to isovaleryl-CoA. That complex needs thiamine pyrophosphate, lipoamide, coenzyme A, FAD and NAD, so five separate B vitamin derived cofactors sit on one reaction.
A minor cytosolic route sends KIC through KIC dioxygenase to beta-hydroxy-beta-methylbutyrate. This is the biochemical link between leucine intake and circulating HMB.
Where Ketoisocaproic Acid KIC comes from.
There is no food you press this out of. Makers either build the molecule in a reactor or take leucine, made by fermenting sugar with bacteria, and strip its nitrogen off enzymatically, which is the same step your own muscle performs. The acid that results is sticky and sour, so it is neutralised with calcium or sodium into a powder you can put in a capsule.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Two distinct starting points. The chemical route builds the branched five-carbon skeleton from petrochemical or bio-based intermediates. The biocatalytic route starts from L-leucine, which is itself produced by fermentation of glucose with Corynebacterium glutamicum strains.
Chemically, the keto-acid is assembled and oxidised to the 2-oxo position. Enzymatically, L-amino acid oxidase or a transaminase removes leucine's amino group, which is the same reaction the body performs, run in a reactor.
Unreacted leucine, the amino donor or acceptor, and synthesis by-products are separated by crystallisation or ion exchange. Residual leucine is the specification item to watch, since it is both the precursor and the likeliest contaminant.
The free keto-acid is hygroscopic and acidic, so it is neutralised with calcium or sodium hydroxide, or paired with ornithine, to give a handleable powder. This step is what makes the material shippable and blendable.
Batches are assayed for keto-acid content, with the counter-ion share and residual amino acid stated. Because the salts differ in molecular weight, comparing two products means comparing keto-acid content, not gross powder weight.
The salt is milled and either capsuled or blended into a powdered formula, usually with the branched-chain amino acids and the B vitamin cofactors of the pathway.
Labels almost never say whether the route was chemical synthesis or enzymatic conversion from leucine, and they often state gross milligrams without naming the counter-ion, which leaves the actual keto-acid dose unstated.
The forms it comes in.
The essence, in one line each.
- In healthy young men, ingesting branched-chain ketoacids raised measured muscle protein synthesis rates, as did the matching branched-chain amino acids.Randomised trial. Fuchs et al., 2019 (The American journal of clinical nutrition). PMID 31250889 ↗
- Beta-hydroxy-beta-methylbutyrate taken together with alpha-ketoisocaproic acid reduced measured signs and reported symptoms of muscle damage after unaccustomed exercise.Randomised trial. van Someren et al., 2005 (International journal of sport nutrition and exercise metabolism). PMID 16286672 ↗
- A later randomised trial did not detect a reduction in exercise-induced muscle damage from beta-hydroxy-beta-methylbutyrate combined with alpha-ketoisocaproic acid, which is a failure to detect a difference rather than proof of none.Randomised trial. Nunan et al., 2010 (Journal of strength and conditioning research). PMID 20072045 ↗
- Branched-chain ketoacids influenced glucose transport through mTORC1-dependent signalling, and raising BCAA catabolism changed that effect in the other direction.In vitro study. Mann et al., 2024 (Journal of Nutritional Science). PMID 39464407 ↗
These are the studies our verdict leans on, chosen from the 326 we read for Ketoisocaproic Acid KIC. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.